BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28368667)

  • 1. One-step formation of lipid-polyacrylic acid-calcium carbonate nanoparticles for co-delivery of doxorubicin and curcumin.
    Peng J; Fumoto S; Miyamoto H; Chen Y; Kuroda N; Nishida K
    J Drug Target; 2017 Sep; 25(8):704-714. PubMed ID: 28368667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
    Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
    Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pH-Responsive prodrug nanoparticles based on a sodium alginate derivative for selective co-release of doxorubicin and curcumin into tumor cells.
    Gao C; Tang F; Gong G; Zhang J; Hoi MPM; Lee SMY; Wang R
    Nanoscale; 2017 Aug; 9(34):12533-12542. PubMed ID: 28819666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
    Wang L; Wang W; Rui Z; Zhou D
    Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
    Cui T; Zhang S; Sun H
    Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designed Synthesis of Lipid-Coated Polyacrylic Acid/Calcium Phosphate Nanoparticles as Dual pH-Responsive Drug-Delivery Vehicles for Cancer Chemotherapy.
    Wang X; Zhang M; Zhang L; Li L; Li S; Wang C; Su Z; Yuan Y; Pan W
    Chemistry; 2017 May; 23(27):6586-6595. PubMed ID: 28218434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistically Improved Anti-tumor Efficacy by Co-delivery Doxorubicin and Curcumin Polymeric Micelles.
    Wang J; Ma W; Tu P
    Macromol Biosci; 2015 Sep; 15(9):1252-61. PubMed ID: 25981672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
    Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
    Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
    Zhao P; Wu S; Cheng Y; You J; Chen Y; Li M; He C; Zhang X; Yang T; Lu Y; Lee RJ; He X; Xiang G
    Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer.
    Zhao X; Chen Q; Liu W; Li Y; Tang H; Liu X; Yang X
    Int J Nanomedicine; 2015; 10():257-70. PubMed ID: 25565818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer.
    Zhang Y; Yang C; Wang W; Liu J; Liu Q; Huang F; Chu L; Gao H; Li C; Kong D; Liu Q; Liu J
    Sci Rep; 2016 Feb; 6():21225. PubMed ID: 26876480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets.
    Baghbani F; Moztarzadeh F
    Colloids Surf B Biointerfaces; 2017 May; 153():132-140. PubMed ID: 28235723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amifostine-conjugated pH-sensitive calcium phosphate-covered magnetic-amphiphilic gelatin nanoparticles for controlled intracellular dual drug release for dual-targeting in HER-2-overexpressing breast cancer.
    Li WM; Chiang CS; Huang WC; Su CW; Chiang MY; Chen JY; Chen SY
    J Control Release; 2015 Dec; 220(Pt A):107-118. PubMed ID: 26478017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-assembly of doxorubicin and curcumin targeted micelles for synergistic delivery and improving anti-tumor efficacy.
    Ma W; Guo Q; Li Y; Wang X; Wang J; Tu P
    Eur J Pharm Biopharm; 2017 Mar; 112():209-223. PubMed ID: 27913127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
    Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
    Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors.
    Jiang H; Geng D; Liu H; Li Z; Cao J
    Drug Deliv; 2016 Nov; 23(9):3665-3673. PubMed ID: 27749102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic core-shell nanocapsules with dual-targeting capabilities and co-delivery of multiple drugs to treat brain gliomas.
    Fang JH; Lai YH; Chiu TL; Chen YY; Hu SH; Chen SY
    Adv Healthc Mater; 2014 Aug; 3(8):1250-60. PubMed ID: 24623647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ mineralization of anticancer drug into calcium carbonate monodisperse nanospheres and their pH-responsive release property.
    Yang T; Wan Z; Liu Z; Li H; Wang H; Lu N; Chen Z; Mei X; Ren X
    Mater Sci Eng C Mater Biol Appl; 2016 Jun; 63():384-92. PubMed ID: 27040233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach.
    Tefas LR; Sylvester B; Tomuta I; Sesarman A; Licarete E; Banciu M; Porfire A
    Drug Des Devel Ther; 2017; 11():1605-1621. PubMed ID: 28579758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.